# Phase II Study of Sipuleucel-T and Indoximod for Patients With Refractory Metastatic Prostate Cancer

> **NCT01560923** · PHASE2 · COMPLETED · sponsor: **Masonic Cancer Center, University of Minnesota** · enrollment: 47 (actual)

## Conditions studied

- Metastatic Prostate Cancer

## Interventions

- **BIOLOGICAL:** Indoximod
- **BIOLOGICAL:** Sipuleucel-T
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT01560923
- **Lead sponsor:** Masonic Cancer Center, University of Minnesota
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-10-01
- **Primary completion:** 2018-12-12
- **Final completion:** 2018-12-12
- **Target enrollment:** 47 (ACTUAL)
- **Last updated:** 2020-04-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01560923

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01560923, "Phase II Study of Sipuleucel-T and Indoximod for Patients With Refractory Metastatic Prostate Cancer". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT01560923. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*